TY - JOUR
T1 - Allergen immunotherapy for insect venom allergy
T2 - protocol for a systematic review
AU - Dhami, Sangeeta
AU - Nurmatov, Ulugbek
AU - Varga, Eva-Maria
AU - Sturm, Gunter
AU - Muraro, Antonella
AU - Akdis, Cezmi A.
AU - Antolin-Amerigo, Dario
AU - Bilo, M. Beatrice
AU - Bokanovic, Danijela
AU - Calderon, Moises A.
AU - Cichocka-Jarosz, Ewa
AU - Oude Elberink, H. N. G.
AU - Gawlik, Radoslaw
AU - Jakob, Thilo
AU - Kosnik, Mitja
AU - Lange, Joanna
AU - Mingomataj, Ervin
AU - Mitsias, Dimitris I.
AU - Mosbech, Holger
AU - Pfaar, Oliver
AU - Pitsios, Constantinos
AU - Pravettoni, Valerio
AU - Roberts, Graham
AU - Rueeff, Franziska
AU - Sin, Betul Ayse
AU - Sheikh, Aziz
PY - 2016/2/16
Y1 - 2016/2/16
N2 - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Insect Venom Allergy. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy.Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised.Discussion: The findings from this review will be used to inform the development of recomendations for EAACI's Guidelines on AIT.
AB - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Insect Venom Allergy. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy.Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised.Discussion: The findings from this review will be used to inform the development of recomendations for EAACI's Guidelines on AIT.
KW - Allergy
KW - Insect sting
KW - Hymenoptera venom allergy
KW - Insect venom allergy
KW - Allergen immunotherapy
KW - Systemic sting reaction
KW - HYMENOPTERA VENOM
KW - ANAPHYLAXIS
KW - EPIDEMIOLOGY
KW - MANAGEMENT
KW - CHILDREN
KW - BIAS
U2 - 10.1186/s13601-016-0095-x
DO - 10.1186/s13601-016-0095-x
M3 - Article
SN - 2045-7022
VL - 6
JO - Clinical and translational allergy
JF - Clinical and translational allergy
M1 - 6
ER -